Glucarpidase efficacy in mitigating methotrexate toxicity is unaffected by concurrent administration of folinic acid
Martin Wahlestedt, Karin Hansson, Alexandra Bill, Anders Isaksson, Jesper Heldrup, Cornelis Jan Pronk · 2026
Read Glucarpidase efficacy in mitigating methotrexate toxicity is unaffected by concurrent administration of folinic acid by Martin Wahlestedt, Karin Hansson, Alexandra Bill, Anders Isaksson, Jesper Heldrup, Cornelis Jan Pronk (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13156163.txt.
Description
Martin Wahlestedt and co-authors test, in a 2026 study, whether two rescue drugs for a cancer therapy clash when given together. High-dose methotrexate is a mainstay for children's cancers, but slow clearance can poison the body. Rescue pairs folinic acid, a vitamin-like shield, with glucarpidase, an enzyme that chews up the drug. Guides advise pausing the shield near the enzyme dose, fearing it might block the rescue.
The team built a lab model with human plasma spiked with both drugs, and added blood from young patients on treatment. The enzyme cleared over ninety-nine percent of the cancer drug fast, whether the shield was present or not. It did chew up part of the shield itself, which may call for dose tweaks later. The findings suggest the shield need not be paused, a change the authors say needs clinical proof.
Catalog record
| CREATOR | Martin Wahlestedt, Karin Hansson, Alexandra Bill, Anders Isaksson, Jesper Heldrup, Cornelis Jan Pronk |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |